FDA allows wider use of 2 hepatitis drugs from Schering

03/11/2009 | Forbes

Schering-Plough received FDA clearance to market its hepatitis C drugs Pegintron and Rebetol for patients with compensated liver disease who no longer respond to previous treatment. The drugs are approved as initial treatment in patients age 3 and older.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA